Find practical information about diabetes treatment and management, including blood sugar monitoring, medications, lifestyle changes, complications and everyday diabetes care.
Once primarily associated with diabetes and obesity, GLP-1 drugs are now being explored for their potential to treat a range of conditions including heart and kidney disease, sleep apnoea, cancer, and addiction, signalling a significant shift in their clinical use.…
Research indicates that sodium-glucose cotransporter-2 inhibitors could influence bone biology earlier than standard tests reveal, raising questions about their long-term skeletal safety. A new study in the journal Diabetes, Obesity and Metabolism adds to the debate over whether sodium-glucose cotransporter-2…
A recent review of 73,220 participants found that SGLT2 inhibitors provide consistent heart and kidney benefits across different stages of CKM syndrome, including severe cases, highlighting their potential for broader application in integrated cardiorenal care. A large review in BMC…
A pooled analysis of large clinical trials suggests tirzepatide may enhance blood sugar control and reduce weight gain when added to basal insulin in adults with longstanding type 2 diabetes, offering new hope for intensifying treatment without additional hypoglycaemia risk.…
Abbott Laboratories has received FDA clearance for its new Libre Duo 10 Day wearable device, the first in the US to continuously monitor both glucose and ketone levels, potentially transforming diabetes management and risk detection. Abbott Laboratories has won US…
A recent mouse study presented at ENDO 2026 complicates the view that cutting sugar automatically improves metabolic health, highlighting the nuanced role of dietary carbohydrates in gut and immune function and warning against extreme restrictions. A new mouse study presented…
The US Food and Drug Administration has authorised the Libre Duo 10 Day system, a groundbreaking wearable that tracks glucose and ketone levels simultaneously, potentially transforming diabetic ketoacidosis prevention and management. The US Food and Drug Administration has authorised the…
As GLP-1 treatments like semaglutide and liraglutide reduce appetite and alter digestion, experts emphasise the importance of tracking diet, hydration and micronutrients to prevent deficiencies and support overall health. People taking GLP-1 medicines may find that eating less feels almost…
Despite a new Medicare pilot programme aimed at making GLP-1 weight-loss medications more affordable, restrictions based on health conditions leave out many patients, including a retired professor with severe obesity and health issues. Jeff La Marca thought he had found…
While clinical trials show significant weight regain after stopping GLP-1 medicines like semaglutide and tirzepatide, recent real-world research highlights the potential for sustained progress through follow-up care and lifestyle modifications, underscoring the importance of personalised long-term approaches. Research on GLP-1…
The US Food and Drug Administration has documented over 1,700 adverse-event reports related to illegal compounded versions of semaglutide and tirzepatide, amid rising regulatory scrutiny and ongoing market disputes in the lucrative obesity drug sector. The US Food and Drug…
With summer travel underway, Diabetes UK and footwear brand Gentle Grip warn that walking barefoot on hot sand or beaches can cause severe foot problems for diabetics, urging protective measures to prevent infections and amputations. People with diabetes are being…
